Anand
AI Engineer, Thematic Stock & Crypto Trader, Fundamental & Technical Analysis
Tempus AI's thesis remains intact after objectively strong earnings and a guidance raise. It looks less threatened by Anthropic than other software names because its datasets form its moat, for now. Software multiples remain a big question, and these stocks are struggling to catch a break, but the technical setup still looks good despite the pullback. x.comÂ
Tempus AI has a data moat no one has replicated: a multimodal, patient-linked genomic, clinical and imaging dataset at scale. It holds over 8 million imaging files, 1.5 million matched clinical and molecular profiles and 4.5 million sequencing samples, which drug companies leaning on AI increasingly need. It is expanding from oncology into cardiology, neuropsychiatry and radiology. Revenue grows 25% and gross margin rose from 32% in 2021 to 64%, though last quarter's profit was a one-time item. … Show more
Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.comÂ
Tempus AI could be a picks-and-shovels play on AI pharma, since its data was reportedly used in Moderna's cancer cure development process. It is a speculative holding: whether the company is legitimate is hard to tell. x.comÂ
Tempus AI's selloff after it beat and raised guidance looks like a great deal, and a further drop would be a chance to buy more. x.comÂ
Tempus AI is a second- or third-tier genomic lab whose AI story is marketing mumbo jumbo, and its management team are promoters. x.comÂ
Tempus AI's acquisition of Personalis gives it the technology platform behind Moderna's and Merck's recent cancer-vaccine advances. x.comÂ
Tempus AI is applying Palantir's playbook to US healthcare. Proprietary data from more than 5,000 hospitals and two-thirds of US academic centers let it train a healthcare AI no one else can. At 4x sales it is priced like a lab, though it is an AI company. x.comÂ
Tempus AI may go lower near term because of valuation, leadership reputation and insider selling, despite an amazing business. With about 25% growth expected and profitability uncertain, it is not obviously cheap. Glassdoor reviews matter in medicine's high-trust setting, and ongoing insider sales echo founder patterns that ended badly. The data piece, about 5% of market cap, can earn a high multiple, so the stock looks reasonably priced if adoption continues. x.comÂ
SiTime, Tempus AI and Lemonade look like AI beneficiaries that need not rely on rising frontier-model spending, unlike a crowded trade vulnerable to concentrated capital and circular financing. SiTime can expand into robotics even if data-center growth slows; clinical decisions still need Tempus; Lemonade's models may improve loss ratios and retention while lower compute costs could help it. x.comÂ